<- Go Home
Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Market Cap
CAD 20.5M
Volume
77.4K
Cash and Equivalents
N/A
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
CAD 0.11
52 Week Low
CAD 0.06
Dividend
N/A
Price / Book Value
-0.22
Price / Earnings
-1.68
Price / Tangible Book Value
-0.21
Enterprise Value
CAD 111.9M
Enterprise Value / EBITDA
-23.45
Operating Income
N/A
Return on Equity
11.72%
Return on Assets
-40.29
Cash and Short Term Investments
N/A
Debt
CAD 91.4M
Equity
N/A
Revenue
N/A
Unlevered FCF
-CAD 1.3M
Sector
Biotechnology
Category
N/A